<DOC>
	<DOCNO>NCT01793051</DOCNO>
	<brief_summary>The goal clinical research study learn minocycline help reduce symptom report patient MM receive therapy lenalidomide . Minocycline antibiotic show interrupt pro-inflammatory cytokine production , may help reduce multiple symptom .</brief_summary>
	<brief_title>Intervention Symptom Burden During Maintenance Therapy Multiple Myeloma</brief_title>
	<detailed_description>Study Groups : If participant agrees take part study , randomly assign ( flip coin ) 1 2 group . Group 1 take placebo maintenance therapy . Group 2 take minocycline maintenance therapy . A placebo drug . It look like study drug design treat disease illness . It design compare study drug learn study drug real effect . Neither participant study staff know participant receiving study drug placebo . However , need participant 's safety , study staff able find receiving . Study Drug Administration : Participant take study drug/placebo mouth , two time day 3 month , start first day ( within 2 day ) begin lenalidomide therapy . Participant take study drug/placebo full glass ( 8 ounce ) water . Participant may take without food , study drug/placebo cause upset stomach , participant take food . Study Visits : Participant must bring study drug/placebo container , along remain drug , clinic visit new cycle lenalidomide therapy , clinic visit study clinic visit schedule . Before participant start lenalidomide therapy : - Participant fill 4 questionnaire pain symptom . It take 20-25 minute complete questionnaire . - A study staff member ask participant question demographic information , marital status , job status , education , race . - Blood ( 2 tablespoon ) draw biomarker testing . This already schedule blood draw participant would need extra needle stick . Biomarkers find blood/tissue may relate participant 's reaction study drug . Researchers want study change biomarkers may relate symptom report participant study . During lenalidomide therapy : Â°Participant complete symptom questionnaire clinic telephone 1 time week symptom may may affect participant 's daily activity . The symptom questionnaire take 3-5 minute complete time . During participant 's clinic visit new cycle lenalidomide therapy : - Participant fill 3 questionnaire pain symptom . It take 15-20 minute complete questionnaire time . If clinic visit schedule study , questionnaire collect phone study coordinator . - Blood ( 2 tablespoon ) draw biomarker testing . This already schedule blood draw participant would need extra needle stick . End-of-Treatment Visit : Participant end-of-treatment visit end month 3 . At visit , participant complete 4 questionnaire pain symptom . It take 20-25 minute complete questionnaire . Blood ( 2 tablespoon ) draw biomarker testing . This already schedule blood draw participant would need extra needle stick . Length Study : Participant may continue take study drug/placebo 3 month . Participant longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction , study doctor think best interest . This investigational study . Minocycline FDA approve commercially available treatment bacterial infection . The use minocycline reduce chemotherapy related side effect patient MM currently use research purpose . Up 88 participant take part study . All enrol MD Anderson Cancer Center .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>1 . Patients pathologically diagnose receive induction chemotherapy , without AuSCT , qualify receive lenalidomidebased maintenance therapy MM . 2 . Patients &gt; = 18 year old . 3 . Patients able render inform consent follow protocol requirement . 4 . Patients speak English ( due patientreported outcome language option , accrue Englishspeaking patient protocol ) . 5 . Patients normal renal function accord MD Anderson testing standard prior renal disease [ screen cut serum creatinine &lt; 1.5 time upper limit normal ] . 6 . Patients normal hepatic function accord MD Anderson testing standard prior liver disease [ screening result total bilirubin must &lt; 1.5 time upper limit normal ; screen result alkaline phosphatase ( ALP ) alanine aminotransferase ( ALT ) must &lt; 2 time upper limit normal ; available , screen result aspartate aminotransferase ( AST ) must &lt; 2 time upper limit normal ] . 1 . Patients take minocycline condition , determine treat physician 2 . Patients hypersensitivity tetracyclines 3 . Women pregnant nursing ; pregnancy confirm urine test 4 . Patients enrol clinical trial symptom management primary outcome 5 . Patients able use telephonebased interactive voice response software due physical limitation ( e.g. , impaired hearing ) 6 . Patients take tetracycline last 15 day 7 . Patients Vitamin K antagonist warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>MM</keyword>
	<keyword>Symptom Burden</keyword>
	<keyword>Symptom reduction</keyword>
	<keyword>Maintenance therapy lenalidomide</keyword>
	<keyword>Minocycline</keyword>
	<keyword>Dynacin</keyword>
	<keyword>Minocin</keyword>
	<keyword>Minocin PAC</keyword>
	<keyword>Myrac</keyword>
	<keyword>Solodyn</keyword>
	<keyword>Placebo</keyword>
	<keyword>Sugar pill</keyword>
	<keyword>MD Anderson Symptom Inventory</keyword>
	<keyword>MDASI</keyword>
	<keyword>Questionnaires</keyword>
	<keyword>Surveys</keyword>
</DOC>